AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9390586 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with morphine (0.05 mg/kg bolus, 0.02 mg/kg on demand every 10 min)
Number of subjects: 124
Study 7896423 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1) intravenously (10 ng/kg/min) during surgery
Number of subjects: 31
Study 7896423 — intervention group
Group type: COMPARATOR
Intervention: Control (no PGE1)
Number of subjects: 31
Study 3170796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel sulfate in petrolatum
Number of subjects: 12
Study 3170796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel sulfate in aqueous solutions
Number of subjects: 12
Study 3170796 — intervention group
Group type: EXPERIMENTAL
Intervention: Nickel bioavailability from earrings and necklace
Number of subjects: 12
Study 3170796 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma solution for leaching
Number of subjects: 12
Study 3170796 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline solution and synthetic sweat
Number of subjects: 12
Study 30187612 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG‐IFN add‐on
Number of subjects: 96
Study 30187612 — intervention group
Group type: COMPARATOR
Intervention: ETV monotherapy
Number of subjects: 96
Study 27352373 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical arthroplasty
Number of subjects: 47
Study 27352373 — intervention group
Group type: COMPARATOR
Intervention: ACDF
Number of subjects: 47
Study 25666517 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain educational intervention (30 minute face-to-face meeting, leaflet, follow-up telephone call at two weeks)
Number of subjects: 182
Study 25666517 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 182
Study 23438937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (150 mg daily)
Number of subjects: 326
Study 23438937 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (45 mg daily)
Number of subjects: 326
Study 23438937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 23438937 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 326
Study 23438937 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 326
Study 20953794 — intervention group
Group type: EXPERIMENTAL
Intervention: Submaximal contractions (10-70% MVC)
Number of subjects: 28
Study 20953794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained contraction (10% MVC for 5 min)
Number of subjects: 28
Study 18276741 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab 1 g (2 infusions)
Number of subjects: 17
Study 18276741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 16153764 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 80 mJ/2 Hz, 11 mm distance
Number of subjects: 30
Study 16153764 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 80 mJ/2 Hz, 12 mm distance
Number of subjects: 30
Study 16153764 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 80 mJ/2 Hz, 14 mm distance
Number of subjects: 30
Study 16153764 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 80 mJ/2 Hz, 16 mm distance
Number of subjects: 30
Study 16153764 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 80 mJ/2 Hz, 17 mm distance
Number of subjects: 30
Study 16153764 — intervention group
Group type: COMPARATOR
Intervention: Control group (phosphoric acid alone)
Number of subjects: 30
Study 15000410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric estimation method for quantiles with correlated failure time data.
Number of subjects: 0
Study 15000410 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation studies to investigate finite sample properties of the proposed estimators.
Number of subjects: 0
Study 15000410 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustration of the proposed method with a data set from a study of patients with otitis media.
Number of subjects: 0
Study 10826418 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic restorative proctocolectomy
Number of subjects: 40
Study 8865128 — intervention group
Group type: EXPERIMENTAL
Intervention: CDDP 40 mg/m2 + VP16 100 mg/m2 day 1‐3 (arm A)
Number of subjects: 70
Study 8865128 — intervention group
Group type: COMPARATOR
Intervention: CBDCA 250 mg/m2 day 1 + CDDP 30 mg/m2 day 2, 3 + VP16 100 mg/m2 day 1‐3 (arm B)
Number of subjects: 70
Study 1641586 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine once daily
Number of subjects: 71
Study 1641586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 6567853 — intervention group
Group type: EXPERIMENTAL
Intervention: Four rotation postures (specific postures not detailed)
Number of subjects: 100
Study 6567853 — intervention group
Group type: EXPERIMENTAL
Intervention: Sims posture (maintenance posture)
Number of subjects: 100
Study 6567853 — intervention group
Group type: COMPARATOR
Intervention: Control posture
Number of subjects: 100
Study 30790648 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-first group
Number of subjects: 133
Study 30790648 — intervention group
Group type: COMPARATOR
Intervention: Phone-first group
Number of subjects: 133
Study 29557400 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mm implants
Number of subjects: 80
Study 29557400 — intervention group
Group type: COMPARATOR
Intervention: 10.0 mm or longer implants
Number of subjects: 80
Study 27371187 — intervention group
Group type: EXPERIMENTAL
Intervention: Attention Process Training‐II program
Number of subjects: 44
Study 27371187 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 44
Study 25263780 — intervention group
Group type: EXPERIMENTAL
Intervention: Control enriched with 100 g/kg of extruded linseed
Number of subjects: 3
Study 25263780 — intervention group
Group type: EXPERIMENTAL
Intervention: Control enriched with 200 g/kg of extruded linseed
Number of subjects: 3
Study 25263780 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermised milk with starter culture
Number of subjects: 3
Study 25263780 — intervention group
Group type: COMPARATOR
Intervention: Raw milk cheeses
Number of subjects: 3
Study 23092644 — intervention group
Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 360
Study 23092644 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 360
Study 20145166 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/d)
Number of subjects: 161
Study 20145166 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 day 1 every 3 weeks)
Number of subjects: 161
Study 18042476 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (mecobalamin 500 mg + multivitamin supplement containing B6 5 mg, folic acid 1 mg)
Number of subjects: 89
Study 18042476 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 18042476 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation
Number of subjects: 89
Study 11240506 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterography
Number of subjects: 38
Study 11240506 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal sonohysterography
Number of subjects: 38
Study 11240506 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Number of subjects: 38
Study 9429363 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvinyl chloride (PVC) device
Number of subjects: 71
Study 9429363 — intervention group
Group type: COMPARATOR
Intervention: Disposable nursing pad
Number of subjects: 71
Study 8389269 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (100 U/mL)
Number of subjects: 12
Study 8389269 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ulinastatin)
Number of subjects: 12
Study 3548612 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% branched chain enriched formula (MAA) (Travasol + Branchamin concentrate) at a dose of 1.0-2.0 g/kg/day
Number of subjects: 87
Study 3548612 — intervention group
Group type: COMPARATOR
Intervention: Standard amino acid formula (SAA) (Travasol) at a dose of 1.0-2.0 g/kg/day
Number of subjects: 87
Study 31715580 — intervention group
Group type: EXPERIMENTAL
Intervention: Positively framed self-efficacy questionnaire
Number of subjects: 275
Study 31715580 — intervention group
Group type: COMPARATOR
Intervention: Negatively framed self-efficacy questionnaire
Number of subjects: 275
Study 30025526 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstruction with bone cement and cancellous screws (R group)
Number of subjects: 20
Study 30025526 — intervention group
Group type: COMPARATOR
Intervention: No reconstruction (NR group)
Number of subjects: 20
Study 28778151 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm of muscle function tests (four tests: arm lift, head lift, swallowing or eye opening)
Number of subjects: 165
Study 28778151 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncalibrated acceleromyography
Number of subjects: 165
Study 28778151 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile judgement of TOF fading
Number of subjects: 165
Study 28778151 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm of muscle function tests
Number of subjects: 165
Study 24382021 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Intervals (SI)
Number of subjects: 16
Study 24382021 — intervention group
Group type: COMPARATOR
Intervention: Long Intervals (LI)
Number of subjects: 16
Study 24246427 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging intervention (n=26)
Number of subjects: 50
Study 24246427 — intervention group
Group type: COMPARATOR
Intervention: Education control arm (n=24)
Number of subjects: 50
Study 24246427 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging adherence
Number of subjects: 50
Study 24246427 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging adherence and weight loss correlation
Number of subjects: 50
Study 21051593 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-based training with manual assistance (TM)
Number of subjects: 74
Study 21051593 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-based training with stimulation (TS)
Number of subjects: 74
Study 21051593 — intervention group
Group type: EXPERIMENTAL
Intervention: Overground training with stimulation (OG)
Number of subjects: 74
Study 21051593 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-based training with robotic assistance (LR)
Number of subjects: 74
Study 18323476 — intervention group
Group type: COMPARATOR
Intervention: AR genetic variation (haplotype-tagging single nucleotide polymorphisms and CAG repeat number)
Number of subjects: 300
Study 18323476 — intervention group
Group type: COMPARATOR
Intervention: CAG repeat length >or=21 or >or=22
Number of subjects: 300
Study 17147104 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression equations based on age, gender, and estimated premorbid IQ as predictors
Number of subjects: 272
Study 17147104 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and premorbid IQ
Number of subjects: 272
Study 17147104 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 272
Study 12698766 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) intervention
Number of subjects: 0
Study 12698766 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 11063440 — intervention group
Group type: EXPERIMENTAL
Intervention: Pork diet (29% of energy as fat and 29% as protein, mainly from pork meat)
Number of subjects: 12
Study 11063440 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy diet (29% of energy as fat and 28% as protein, mainly from soy)
Number of subjects: 12
Study 11063440 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate diet (28% of energy as fat and 11% as protein)
Number of subjects: 12
Study 8814468 — intervention group
Group type: EXPERIMENTAL
Intervention: DEEF
Number of subjects: 20
Study 8814468 — intervention group
Group type: COMPARATOR
Intervention: PEEP
Number of subjects: 20
Study 8814468 — intervention group
Group type: COMPARATOR
Intervention: IPPV
Number of subjects: 20
Study 1382291 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythemagenic doses of UVB prior to sensitization with DNCB
Number of subjects: 0
Study 1382291 — intervention group
Group type: EXPERIMENTAL
Intervention: Suberythemagenic UV exposure
Number of subjects: 0
Study 1382291 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythemagenic doses of UVB
Number of subjects: 0
Study 1382291 — intervention group
Group type: EXPERIMENTAL
Intervention: Localized moderate sunburn
Number of subjects: 0
Study 29907082 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (Div group)
Number of subjects: 120
Study 29907082 — intervention group
Group type: COMPARATOR
Intervention: 0.5 μg/kg paravertebral dexmedetomidine as an adjuvant to ropivacaine (RD0.5 group)
Number of subjects: 120
Study 29907082 — intervention group
Group type: COMPARATOR
Intervention: 1.0 μg/kg paravertebral dexmedetomidine as an adjuvant to ropivacaine (RD1.0 group)
Number of subjects: 120
Study 29907082 — intervention group
Group type: COMPARATOR
Intervention: 2.0 μg/kg paravertebral dexmedetomidine as an adjuvant to ropivacaine (RD2.0 group)
Number of subjects: 120
Study 29907082 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine (R group)
Number of subjects: 120
Study 29907082 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (C group)
Number of subjects: 120
Study 27804273 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (duration: 18 months)
Number of subjects: 52
Study 23257166 — intervention group
Group type: EXPERIMENTAL
Intervention: FATaintPHAT intervention
Number of subjects: 883
Study 22317271 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality based therapy (VRBT)
Number of subjects: 29
Study 22317271 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study 20013927 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g co-amoxiclav (prophylactic dose)
Number of subjects: 443
Study 20013927 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (control)
Number of subjects: 443
Study 20013927 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics
Number of subjects: 443
Study 18226045 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene treatment
Number of subjects: 100
Study 18226045 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study 16755158 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-coated dialyzer
Number of subjects: 16
Study 12960599 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-corrected (NC) images
Number of subjects: 607
Study 12960599 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation- and scatter-corrected (AC-SC) images
Number of subjects: 607
Study 12960599 — intervention group
Group type: COMPARATOR
Intervention: Combined evaluation of NC and AC-SC images
Number of subjects: 607
Study 12960599 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation and scatter correction
Number of subjects: 607
Study 10730687 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban 125-microg/kg bolus followed by 4-hour continuous infusion of 2.5 microg/kg/minute (Study 1)
Number of subjects: 40
Study 10730687 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban 4-hour infusion of 2.5 microg/kg/minute (Study 2)
Number of subjects: 40
Study 10730687 — intervention group
Group type: EXPERIMENTAL
Intervention: Argatroban 5-microg/kg/minute continuous infusion over 4 hours (Study 3)
Number of subjects: 40
Study 8703452 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 16
Study 8703452 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 16
Study 1572183 — intervention group
Group type: EXPERIMENTAL
Intervention: iv ranitidine to increase gastric pH greater than 4
Number of subjects: 34
Study 1572183 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis for upper gastrointestinal bleeding (control group)
Number of subjects: 34
Study 3966507 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual manipulation of the fetus prior to the nonstress test
Number of subjects: 790
Study 3966507 — intervention group
Group type: COMPARATOR
Intervention: No manual manipulation of the fetus (control group)
Number of subjects: 790
Study 31201218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC) 5 g once daily on non-dialysis days, titrated to a maximum of 15 g over 4 weeks.
Number of subjects: 196
Study 31201218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study 31201218 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate (SZC)
Number of subjects: 196
Study 29717473 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalable doxorubicin (25 mg/m2)
Number of subjects: 240
Study 29717473 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (10 mg/m2)
Number of subjects: 240
Study 26786584 — intervention group
Group type: EXPERIMENTAL
Intervention: Brisk walking program (78 sessions over 6 months, 3 sets of 60 min of exercise per week)
Number of subjects: 121
Study 24960516 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (50 mg/day)
Number of subjects: 284
Study 24960516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 22935482 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria at 1-2 μg/min
Number of subjects: 1208
Study 22935482 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient population
Number of subjects: 1208
Study 22935482 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 1208
Study 22935482 — intervention group
Group type: COMPARATOR
Intervention: ACEI therapy
Number of subjects: 1208
Study 19962275 — intervention group
Group type: EXPERIMENTAL
Intervention: Right ventricular septal (RVS) pacing
Number of subjects: 46
Study 19962275 — intervention group
Group type: COMPARATOR
Intervention: Right ventricular apical (RVA) pacing
Number of subjects: 46
Study 18496484 — intervention group
Group type: EXPERIMENTAL
Intervention: Amine fluoride/stannous fluoride (AmF-SnF(2))
Number of subjects: 30
Study 18496484 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine 0.12% (CHX) followed by AmF-SnF(2)
Number of subjects: 30
Study 15803299 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 10
Study 15803299 — intervention group
Group type: EXPERIMENTAL
Intervention: Metaraminol
Number of subjects: 10
Study 12440139 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of INH per day for 6 months
Number of subjects: 29
Study 12440139 — intervention group
Group type: COMPARATOR
Intervention: Follow-up by chest X-ray
Number of subjects: 29
Study 10367995 — intervention group
Group type: EXPERIMENTAL
Intervention: Tower of Hanoi test
Number of subjects: 28
Study 10367995 — intervention group
Group type: EXPERIMENTAL
Intervention: WCST
Number of subjects: 28
Study 10367995 — intervention group
Group type: EXPERIMENTAL
Intervention: Discriminant analysis
Number of subjects: 28
Study 10367995 — intervention group
Group type: EXPERIMENTAL
Intervention: Common underlying factor
Number of subjects: 28
Study 8634219 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamils of the plains, Madras City (N = 142)
Number of subjects: 190
Study 8634219 — intervention group
Group type: EXPERIMENTAL
Intervention: Kota tribe (N = 48)
Number of subjects: 190
Study 8634219 — intervention group
Group type: EXPERIMENTAL
Intervention: Family material (N = 54) including 37 offspring
Number of subjects: 190
Study 2325924 — intervention group
Group type: EXPERIMENTAL
Intervention: Group reminiscence counseling
Number of subjects: 60
Study 2325924 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 7028200 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.3 mg/Kg b.wt.)
Number of subjects: 14
Study 7028200 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29843500 — intervention group
Group type: EXPERIMENTAL
Intervention: PCD+PD (percutaneous catheter drainage combined with peritoneal dialysis)
Number of subjects: 64
Study 29843500 — intervention group
Group type: COMPARATOR
Intervention: Convention group (conventional method)
Number of subjects: 64
Study 28556519 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept
Number of subjects: 19
Study 28556519 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 19
Study 28556519 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept (after 3 months of tacrolimus)
Number of subjects: 19
Study 25527488 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 hours of task-specific upper-limb training in the first month poststroke
Number of subjects: 23
Study 25527488 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 23
Study 23816960 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg per day
Number of subjects: 345
Study 23816960 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus pemetrexed chemotherapy
Number of subjects: 345
Study 23816960 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib (specifically for exon 19 deletions and L858R mutations)
Number of subjects: 345
Study 23816960 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 345
Study 21184877 — intervention group
Group type: EXPERIMENTAL
Intervention: Orientation device
Number of subjects: 4
Study 21184877 — intervention group
Group type: COMPARATOR
Intervention: No orientation device
Number of subjects: 4
Study 19430098 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral treatment-experienced patients
Number of subjects: 348
Study 19430098 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral treatment-naive patients
Number of subjects: 348
Study 19430098 — intervention group
Group type: COMPARATOR
Intervention: Comparison of polymerase domain between treatment-experienced and treatment-naive patients
Number of subjects: 348
Study 19430098 — intervention group
Group type: COMPARATOR
Intervention: Comparison of thumb-connection domain between treatment-experienced and treatment-naive patients
Number of subjects: 348
Study 19430098 — intervention group
Group type: COMPARATOR
Intervention: Comparison of RNase H domain between treatment-experienced and treatment-naive patients
Number of subjects: 348